Document is current
Any future updates will be listed below
-
Authors
Wolthuis, David F. G. J.
Nijenhuis, Marga https://orcid.org/0000-0001-7476-6867
Soree, Bianca
de Boer-Veger, Nienke J.
Buunk, Anne Marie
Guchelaar, Henk-Jan
Risselada, Arne
Rongen, Gerard A. P. J. M.
van Schaik, Ron H. N.
Swen, Jesse J. https://orcid.org/0000-0002-3965-5552
Touw, Daan J. https://orcid.org/0000-0002-1429-4789
van Westrhenen, Roos
Deneer, Vera H. M.
Houwink, Elisa J. F. https://orcid.org/0000-0002-9927-7266
- License Information
-
More Information
Article History
Received: 17 July 2024
Revised: 20 November 2024
Accepted: 3 December 2024
First Online: 15 December 2024
Competing interests
: The Pharmacogenetics Working Group of the KNMP (DPWG) formulates the optimal recommendations for each phenotype group based on the available evidence. If this optimal recommendation cannot be followed due to practical restrictions, e.g. therapeutic drug monitoring or a lower dose is not available, then the health care professional should consider the next best option.
